Travere Therapeutics (TVTX) and CSL Vifor (CSLLY) announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion greater than or equal to1.0 g/day. “FILSPARI targets damage directly in the kidney and offers patients a convenient, once daily, oral, non-immunosuppressive treatment that can provide superior results compared to maximally dosed irbesartan, supporting replacing their RASi,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Together with our partner, CSL Vifor, we look forward to people living with IgAN in Switzerland gaining access to this important medicine.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere reports Swissmedic grants temporary marketing authorization for Filspari
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
- Travere Therapeutics initiated with an Outperform at Scotiabank
- Travere Therapeutics price target raised to $30 from $12 at Evercore ISI
- Travere Therapeutics price target raised to $25 from $17 at Wedbush